<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OALibJ</journal-id><journal-title-group><journal-title>Open Access Library Journal</journal-title></journal-title-group><issn pub-type="epub">2333-9705</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oalib.1107605</article-id><article-id pub-id-type="publisher-id">OALibJ-110681</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Business&amp;Economics</subject><subject> Chemistry&amp;Materials Science</subject><subject> Computer Science&amp;Communications</subject><subject> Earth&amp;Environmental Sciences</subject><subject> Engineering</subject><subject> Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject><subject> Social Sciences&amp;Humanities</subject></subj-group></article-categories><title-group><article-title>
 
 
  Preparation of Carbamazepine-Nicotinamide Cocrystal
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Huirong</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jinna</surname><given-names>Zhang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chengjun</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, China</addr-line></aff><aff id="aff1"><addr-line>Zhejiang Hisoar Pharmaceutical Co., Ltd., Taizhou, China</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>06</month><year>2021</year></pub-date><volume>08</volume><issue>07</issue><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>2,</day>	<month>June</month>	<year>2021</year></date><date date-type="rev-recd"><day>17,</day>	<month>July</month>	<year>2021</year>	</date><date date-type="accepted"><day>20,</day>	<month>July</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  The focus of this investigation was to prepare the cocrystal of carbamazepine (CBZ) using nicotinamide as a coformer and to compare its different preparation methods. The cocrystal was prepared by grinding, solvent-Assisted grinding and ultrasound-assisted cocrystallization methods. They were characterized by Fourier transform infrared spectroscopy (FT-IR), powder X-ray diffraction (PXRD), and morphology by electron microscopy. In conclusion, ultrasound can be applied as a process intensification parameter along with cooling or slurry cocrystallization to produce pure cocrystals under conditions that might result in crystal mixtures in conventional processes.
 
</p></abstract><kwd-group><kwd>Carbamazepine</kwd><kwd> Nicotinamide</kwd><kwd> Cocrystal</kwd><kwd> Ultrasound</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Carbamazepine (CBZ) was first approved for the US market by the FDA in 1968 under the brand name Tegretol&#174; and currently approved as an anticonvulsant for selected epileptic seizures and the treatment of pain associated with trigeminal neuralgia [<xref ref-type="bibr" rid="scirp.110681-ref1">1</xref>]. CBZ is an iminostilbene derivative, which is structurally related to tricyclic antidepressants, with anticonvulsive and pain reduction due to a decreased potentiation of synaptic transmission in the affected areas [<xref ref-type="bibr" rid="scirp.110681-ref2">2</xref>]. CBZ is classified as a class 2 drug under the biopharmaceutics classification system [<xref ref-type="bibr" rid="scirp.110681-ref3">3</xref>]. Class 2 drug substances are characterized as having low solubility in an aqueous media, but a high permeability across the human intestinal membrane or an appropriately predictive in vitro model [<xref ref-type="bibr" rid="scirp.110681-ref4">4</xref>]. Therefore, formulation strategies are aimed at improving the solubility and dissolution rates in order to enhance the bioavailability of this highly permeable drug. The existence of a dihydrate and four anhydrous polymorphic forms of CBZ further complicates its formulation [<xref ref-type="bibr" rid="scirp.110681-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.110681-ref6">6</xref>]. CBZ polymorphs have been shown to yield different dissolution profiles and a significant difference in pharmacokinetic profiles when studied in dogs [<xref ref-type="bibr" rid="scirp.110681-ref7">7</xref>]. Nicotinamide (NCT) is a generally recognized as safe class 1 chemical and is often utilized in much larger doses to treat high cholesterol than seen in cocrystal formation [<xref ref-type="bibr" rid="scirp.110681-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.110681-ref9">9</xref>]. Nicotinamide has been widely used as a coformer [<xref ref-type="bibr" rid="scirp.110681-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.110681-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.110681-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.110681-ref13">13</xref>]. The preparation method of cocrystal has very important meaning in the preparation of cocrystal [<xref ref-type="bibr" rid="scirp.110681-ref14">14</xref>]. This article compares the different preparation methods of CBZ-NCT cocrystal, which is of great significance to the preparation of CBZ-NCT cocrystal.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Materials</title><p>Carbamazepine and nicotinamide were purchased from Energy Chemical (Shanghai, China). Solvents were purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd. (Shanghai, China).</p></sec><sec id="s2_2"><title>2.2. Methods</title>Cocrystal Synthesis<p>CBZ-NCT cocrystal was synthesized using grinding, solvent-Assisted grinding and ultrasound-assisted cocrystallization [<xref ref-type="bibr" rid="scirp.110681-ref15">15</xref>].</p></sec><sec id="s2_3"><title>2.3. Characterization of CBZ-NCT Cocrystal</title><p>Fourier Transform Infrared Spectroscopy (FT-IR) spectra were recorded on a Perkin-Elmer Spectrum BX FTIR system, equipped with a deuterium triglycine sulfate detector. The scanrange was 500 - 4000 cm<sup>−</sup><sup>1</sup>, using eight scans per spectrum with a resolution of 1 cm<sup>−</sup><sup>1</sup>. Spectra were obtained in the transmission mode in KBr pellets.</p><p>Powder X-ray diffraction (PXRD) patterns were collected using Rigaku X-ray polycrystalline diffractometer. Samples were placed onto a silicon wafer slide. Generator settings were 40 kV with a current of 40 mA used for the measurement. Data were collected (n = 3) in the range 2θ = 5˚ to 40˚ at a scanning rate of 5˚/min with a scan rate of 0.04˚/time and a slit width of 6.0 mm.</p><p>Microscopy was performed using Bai Datong wireless connection high-definition digital wifi microscope.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Fourier Transform Infrared Spectroscopy</title><p>Also known as dry grinding or solid state grinding, mechanochemical grinding was the more typically used method of cocrystal synthesis. The FT-IR spectra of commercial CBZ and CBZ USP grade, recorded in KBr pellets. <xref ref-type="fig" rid="fig1">Figure 1</xref> shows the FT-IR spectrum of CBZ, NCT, their physical mixture, and cocrystal prepared by solvent-free grinding.</p><p>It can be seen from <xref ref-type="fig" rid="fig1">Figure 1</xref> that through simple solvent-free grinding, CBZ and NCT cannot form a cocrystal. One huge drawback with mechanochemical grinding in the solid state is that, with no heating stage involved in the process, there are numerous cases where the energy required to complete the cocrystallization of compounds is lacking. One method to overcome this is the induction of a small amount of water or a solvent to the ball milling mechanism, which acts as a catalyst assisting the process in a process known as Liquid-assisted grinding (LAG). LAG (also known as solvent-drop grinding or wet granulation) is mediated by a liquid phase.</p><p>Then we use solvent-assisted grinding, and the result is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. <xref ref-type="fig" rid="fig2">Figure 2</xref> shows the FT-IR spectrum of CBZ, NCT, their physical mixture, and cocrystal prepared by grinding with solvent. Dichloromethane (DCM), acetone (CP), n-butyl alcohol (NBA), n-propyl alcohol (NPA), Acetonitrile (ACN), ethyl alcohol (EA).</p><p>It can be seen from <xref ref-type="fig" rid="fig2">Figure 2</xref> that the method of adding liquid to assist grinding cannot be CBZ and NTC to form a cocrystal.</p><p><xref ref-type="fig" rid="fig3">Figure 3</xref> shows the FTIR spectrum of CBZ, NCT, their physical mixture, and cocrystal prepared by ultrasound-assisted cocrystallization.</p><p><xref ref-type="fig" rid="fig3">Figure 3</xref> shows the FTIR spectrum of CBZ, NCT, and ultrasound-assisted cocrystallization prepared by different solvents. The stretching of the primary amide group in CBZ was represented by absorption bands at 3464 and 3163 cm<sup>−</sup><sup>1</sup>, respectively, which could be assigned to the free anti-NH (asymmetrical) and hydrogen-bonded syn-NH (symmetrical) vibration. The absorption band at 1679 cm<sup>−</sup><sup>1</sup> was due to carbonyl (−C=O) stretching. It indicated that when form cocrystal, absorption bands at 3446, 3391 and 3210 cm<sup>−</sup><sup>1</sup>. Absorption bands due to carbonyl (−C=O) andvibrations appeared at 1683 and 1660 cm<sup>−</sup><sup>1</sup>, respectively.</p></sec><sec id="s3_2"><title>3.2. Powder X-Ray Diffraction</title><p><xref ref-type="fig" rid="fig4">Figure 4</xref> shows the PXRD spectrum of CBZ, NCT, their physical mixture prepared by solvent-free grinding.</p><p>It can be seen from <xref ref-type="fig" rid="fig4">Figure 4</xref> that the grinding is only physical mixing.</p><p><xref ref-type="fig" rid="fig5">Figure 5</xref> shows the PXRD spectrum of CBZ, NCT, their physical mixture by grinding with solvent.</p><p>It can be seen from <xref ref-type="fig" rid="fig5">Figure 5</xref> that the grinding by adding a solvent is only a physical mixing.</p><p>It can be seen from <xref ref-type="fig" rid="fig6">Figure 6</xref> that through ultrasound induction, CBZ and NCT have formed cocrystal. The PXRD of CBZ forms showed sharp peaks at 2θ values of 13.0˚, 15.2˚, 15.8˚, 18.6˚, 19.4˚, 23.8˚, 26.68˚, and 27.52˚, respectively. Similarly, the diffractogram of NCT showed peaks at 2θ values of 14.72˚, 22.12˚, 25.72˚, 27.24˚, and 40.28˚. Cocrystal showed sharp peaks at 6.68˚, 8.92˚, 10.2˚, 13.32˚, 20.44˚, 23.04˚, 26.48˚, 28.12˚.</p></sec><sec id="s3_3"><title>3.3. Electron Microscopy</title><p>Solvent is the fundamental and foremost important factor for promoting or inhibiting certain crystal motif and to produce correlated effects to the success of required drug material compatibility for the end-user. The use of different solvents during crystallization profoundly affects the crystal habit of the purifified drug, leading to the variation in raw material characteristics such as flowability, compaction, chemical stability, dissolution and packing. Ultrasound-assisted cocrystallization in different solvent are shown in <xref ref-type="fig" rid="fig7">Figure 7</xref>.</p><p>The effect of solvents on ultrasound-assisted cocrystallization in solution is discussed here. From the captured microscopic images, crystals in different solvents show different morphologies CBZ has polar functional groups as hydroxyl, amide and carbonyl groups and CH as the non-polar. Among the selected solvents, polar protic solvents such as isopropyl alcohol strongly allow them to dissolve both positively and negatively charged species to participate in intermolecular force via hydrogen bonding. Whereas the polar aprotic solvents such as acetone, ethylacetate and acetonitrile solvate only positive ions but not negative ions which results in the lack of hydrogen bonding. This result indicates that the type of solvent dramatically influences the shape of cocrystal with respect to the solubility of solute, solvent polarity, evaporation number of solvent and rate of generation of supersaturation in the solution.</p></sec></sec><sec id="s4"><title>4. Conclusion</title><p>With an increasing interest in cocrystals due to various advantages, demand for largescale cocrystallization techniques is rising. Ultrasound can be applied as a process intensification parameter along with cooling or slurry cocrystallization to produce pure cocrystals under conditions that might result in crystal mixtures in conventional processes. The current research demonstrated that the ultrasound-assisted cocrystallization can be an effective method in the production of CBZ-NCT cocrystals. There is hope that ultrasound-assisted cocrystallization will be realized in industry.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s6"><title>Cite this paper</title><p>Ying, H.R., Zhang, J.N. and Jiang, C.J. (2021) Preparation of Carbamazepine-Nicotinamide Cocrystal. Open Access Library Journal, 8: e7605. https://doi.org/10.4236/oalib.1107605</p></sec></body><back><ref-list><title>References</title><ref id="scirp.110681-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Post, R.M., Uhde, T.W., Roy-Byrne, P.P. and Joffe, R.T. (1986) Antidepressant Effects of Carbamazepine. The American Journal of Psychiatry, 143, 29-34.  
https://doi.org/10.1176/ajp.143.1.29</mixed-citation></ref><ref id="scirp.110681-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Granger, P., Biton, B., Faure, C., Vige, X., Depoortere, H., Graham, D., et al. (2005) Modulation of the Gamma-Aminobutyric Acid Type A Receptor by the Antiepileptic Drugs Carbamazepine and Phenytoin. Molecular Pharmacology, 47, 1189-1196.</mixed-citation></ref><ref id="scirp.110681-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kasim, N.A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennern&amp;auml;s, H., Hussain, A.S., et al. (2003) Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Molecular Pharmacology, 1, 85-96.  
https://doi.org/10.1021/mp034006h</mixed-citation></ref><ref id="scirp.110681-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ku, M.S. (2008) Use of the Biopharmaceutical Classification System in Early Drug Development. The AAPS Journal, 10, 208-212.  
https://doi.org/10.1208/s12248-008-9020-0</mixed-citation></ref><ref id="scirp.110681-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Grzesiak, A.L., Lang, M., Kim, K. and Matzger, A.J. (2003) Comparison of the Four Anhydrous Polymorphs of Carbamazepine and the Crystal Structure of form I. Journal of Pharmaceutical Sciences, 92, 2260-2271.  
https://doi.org/10.1002/jps.10455</mixed-citation></ref><ref id="scirp.110681-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rustichelli, C., Gamberini, G., Ferioli, V., Gamberinig, M.C., Ficarra, R. and Tomasini, S. (2000) Solid-State Study of Polymorphic Drugs: Carbamazepine. Journal of Pharmaceutical and Biomedical Analysis, 23, 41-54.  
https://doi.org/10.1016/S0731-7085(00)00262-4</mixed-citation></ref><ref id="scirp.110681-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kobayashi, Y., Ito, S., Itai, S. and Yamamoto, K. (2000) Physicochemical Properties and Bioavailability of Carbamazepine Polymorphs and Dihydrate. International Journal of Pharmaceutics, 193, 137-146.  
https://doi.org/10.1016/S0378-5173(99)00315-4</mixed-citation></ref><ref id="scirp.110681-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Das, B. and Baruah, J.B. (2011) Supramolecular Synthons and Hydrates in Stabilization of Multicomponent Crystals of Nicotinamide and Isonicotinamide with N-Containing Aromatic Dicarboxylic Acids. Crystal Growth &amp; Design, 11, 5522-5532.  
https://doi.org/10.1021/cg201096c</mixed-citation></ref><ref id="scirp.110681-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Remenar, J.F., Peterson, M.L., Stephens, P.W., Zhang, Z., Zimenkov, Y. and Hickey, M.B. (2007) Celecoxib: Nicotinamide Dissociation Using Excipients to Capture the Cocrystal’s Potential. Molecular Pharmacology, 4, 386-400.  
https://doi.org/10.1021/mp0700108</mixed-citation></ref><ref id="scirp.110681-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Berry, D.J., Seaton, C.C., Clegg, W., Harrington, R.W., Coles, S.J., Horton, P.N., et al. (2008) Applying Hot-Stage Microscopy to Co-Crystal Screening: A Study of Nicotinamide with Seven Active Pharmaceutical Ingredients. Crystal Growth &amp; Design, 8, 1697-1712. https://doi.org/10.1021/cg800035w</mixed-citation></ref><ref id="scirp.110681-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chieng, N., Hubert, M., Saville, D., Rades, T. and Aaltonen, J. (2009) Formation Kinetics and Stability of Carbamazepine-Nicotinamide Cocrystals Prepared by Mechanical Activation. Crystal Growth &amp; Design, 9, 2377-2386.  
https://doi.org/10.1021/cg801253f</mixed-citation></ref><ref id="scirp.110681-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Porter, W., Elie, S. and Matzger, A. (2008) Polymorphism in Carbamazepine Cocrystals. Crystal Growth &amp; Design, 8, 14-16. https://doi.org/10.1021/cg701022e</mixed-citation></ref><ref id="scirp.110681-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cheney, M.L., Shan, N., Healey, E.R., Hanna, M., Wojtas, L., Zaworotko, M.J., et al. (2010) Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine. Crystal Growth &amp; Design, 10, 394-405.  
https://doi.org/10.1021/cg901010v</mixed-citation></ref><ref id="scirp.110681-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Karimi-Jafari, M., Padrela, L., Walker, G.M. and Croker, D.M. (2018) Creating Cocrystals: A Review of Pharmaceutical Cocrystal Preparation Routes and Applications. Crystal Growth &amp; Design, 18, 6370-6387.  
https://doi.org/10.1021/acs.cgd.8b00933</mixed-citation></ref><ref id="scirp.110681-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Douroumis, D., Ross, S.A. and Nokhodchi, A. (2017) Advanced Methodologies for Cocrystal Synthesis. Advanced Drug Delivery Reviews, 117, 178-195.  
https://doi.org/10.1016/j.addr.2017.07.008</mixed-citation></ref></ref-list></back></article>